Searchable abstracts of presentations at key conferences in endocrinology

ea0060nets20 | Translational Science | UKINETS2018

Immunotherapy in NETs

Fazio Nicola

Immunotherapy in neuroendocrine neoplasms (NENs) has been investigating over the years, mainly with interferon-alpha-2b and oncolytic virus, without conclusive results. The new immune checkpoint inhibitors (IC-Is) are in an initial phase of investigation in NENs with no published study so far, apart from Merkel Cell Carcinoma (MCC). For this latter NEN Avelumab has been recently approved by the FDA and EMA in advanced disease irrespective of the line of treatment. From a biolo...

ea0046p28 | (1) | UKINETS2016

Outcome of Surgical Resection after Neoadjuvant Peptide Receptor Radionuclide Therapy (PRRT) for Pancreatic Neuroendocrine Neoplasms: a case-matched analysis

Partelli Stefano , Bertani Emilio , Bartolomei Mirco , Muffatti Francesca , Grana Chiara Maria , Doglioni Claudio , Fazio Nicola , Falconi Massimo

Background: Peptide receptor radionuclide therapy (PRRT) can be an option for advanced pancreatic neuroendocrine neoplasms (PNENs) to allow patients undergo resection. Whether or not neoadjuvant PRRT increases postoperative morbidity remains unclear.Methods: Patients with initially metastatic and/or locally advanced PNEN who underwent neoadjuvant PRRT (neoadjuvant group) were compared with a group of patients who underwent upfront surgery (control group)...

ea0037gp.28.01 | Endocrine tumours and neoplasia – NETS | ECE2015

Clinicopathologic features, treatments, and survival of patients with ectopic Cushing's syndrome from neuroendocrine tumours: data from an Italian multicentre study

Davi Maria Vittoria , Cosaro Elisa , Piacentini Serena , Reimondo Giuseppe , Albiger Nora , Arnaldi Giorgio , Faggiano Antongiulio , Mantovani Giovanna , Fazio Nicola , Grimaldi Franco , Mannelli Massimo , Giraldi Francesca Pecori , Martini Chiara , Ferone Diego , Campana Davide , Scaroni Carla , Terzolo Massimo , DeMarinis Laura , Francia Giuseppe

Introduction: Available literature on series of patients affected by ectopic Cushing’s syndrome (ECS) deriving from neuroendocrine tumours (NETs) is relatively scarce. This is the first Italian multicentre study regarding clinicopathologic features, modalities of treatment, and survival of patients with NETs and ECS.Patients and methods: Retrospective analysis of data from patients with ECS from NETs collected in 14 centres between 1986 and 2014, ob...

ea0098t5 | Trials In Progress | NANETS2023

Phase 3 LEVEL trial of 177Lu-edotreotide vs everolimus in patients with advanced neuroendocrine tumors of lung or thymic origin (GETNE-T2217)

Capdevila Jaume , Fazio Nicola , Alvarez Rosa , Ansquer Catherine , Baldari Sergio , Baudin Eric , Benavent Marta , Benini Lavinia , Beron Amandine , Berruti Alfredo , Cingarlini Sara , del Olmo-Garcia Maribel , Deshayes Emmanuel , Garcia-Alvarez Alejandro , Garcia-Carbonero Rocio , Haissaguerre Magalie , Hernando Jorge , Anido Herranz Urbano , Jimenez-Fonseca Paula , Lepage Come , Llana Belen , Molina-Cerrillo Javier , Panzuto Francesco , Pubul Virginia , Sansovini Maddalena , Tafuto Salvatore , Taieb David , Teule Alex , Versari Annibale , Villacampa Guillermo , Walter Thomas

Background: Everolimus is the only approved drug for patients with advanced bronchopulmonary neuroendocrine tumors (NET), and there is an urgent unmet need for alternative treatments. Retrospective data for peptide receptor radionuclide therapy (PRRT) have demonstrated promising activity in somatostatin receptor (SST)-positive lung NET. This study aims to investigate the clinical efficacy, safety, and patient-reported outcomes when 177Lu-edotreotide is used to treat...